TY - JOUR
T1 - From interconnection between genes and microenvironment to novel immunotherapeutic approaches in upper gastro-intestinal cancers—A multidisciplinary perspective
AU - Accordino, Giulia
AU - Lettieri, Sara
AU - Bortolotto, Chandra
AU - Benvenuti, Silvia
AU - Gallotti, Anna
AU - Gattoni, Elisabetta
AU - Agustoni, Francesco
AU - Pozzi, Emma
AU - Rinaldi, Pietro
AU - Primiceri, Cristiano
AU - Morbini, Patrizia
AU - Lancia, Andrea
AU - Stella, Giulia Maria
PY - 2020/8
Y1 - 2020/8
N2 - Despite the progress during the last decade, patients with advanced gastric and esophageal cancers still have poor prognosis. Finding optimal therapeutic strategies represents an unmet need in this field. Several prognostic and predictive factors have been evaluated and may guide clinicians in choosing a tailored treatment. Data from large studies investigating the role of immunotherapy in gastrointestinal cancers are promising but further investigations are necessary to better select those patients who can mostly benefit from these novel therapies. This review will focus on the treatment of metastatic esophageal and gastric cancer. We will review the standard of care and the role of novel therapies such as immunotherapies and CAR-T. Moreover, we will focus on the analysis of potential predictive biomarkers such as Modify as: Microsatellite Instability (MSI) and PD-L1, which may lead to treatment personalization and improved treatment outcomes. A multidisciplinary point of view is mandatory to generate an integrated approach to properly exploit these novel antiproliferative agents.
AB - Despite the progress during the last decade, patients with advanced gastric and esophageal cancers still have poor prognosis. Finding optimal therapeutic strategies represents an unmet need in this field. Several prognostic and predictive factors have been evaluated and may guide clinicians in choosing a tailored treatment. Data from large studies investigating the role of immunotherapy in gastrointestinal cancers are promising but further investigations are necessary to better select those patients who can mostly benefit from these novel therapies. This review will focus on the treatment of metastatic esophageal and gastric cancer. We will review the standard of care and the role of novel therapies such as immunotherapies and CAR-T. Moreover, we will focus on the analysis of potential predictive biomarkers such as Modify as: Microsatellite Instability (MSI) and PD-L1, which may lead to treatment personalization and improved treatment outcomes. A multidisciplinary point of view is mandatory to generate an integrated approach to properly exploit these novel antiproliferative agents.
KW - Esophageal cancer
KW - Gastric cancer
KW - Genetics
KW - Immunotherapy
KW - Multidisciplinary
UR - http://www.scopus.com/inward/record.url?scp=85088943588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088943588&partnerID=8YFLogxK
U2 - 10.3390/cancers12082105
DO - 10.3390/cancers12082105
M3 - Review article
AN - SCOPUS:85088943588
VL - 12
SP - 1
EP - 29
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 8
M1 - 2105
ER -